Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CORSYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CORSYM.
ACUVUE THERAVISION WITH KETOTIFEN vs CORSYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction; chlorpheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Adults: 100 mg orally once daily, taken with water at least 1 hour before meals. Maximum dose 100 mg/day.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
The terminal elimination half-life for hydrocodone from the CORSYM formulation is approximately 8-10 hours, reflecting the extended-release profile. This allows for twice-daily dosing. Hydrocodone's half-life in immediate-release forms is about 3-4 hours, so the polistirex complex prolongs absorption. Chlorpheniramine has a half-life of about 20-24 hours in adults, but in the polistirex formulation, its half-life is extended to approximately 18-22 hours, supporting once-daily dosing for the antihistamine component.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
CORSYM (hydrocodone polistirex and chlorpheniramine polistirex) is an extended-release formulation. Hydrocodone is metabolized primarily in the liver via CYP3A4 and CYP2D6 to norhydrocodone, hydromorphone, and other metabolites. Excretion is predominantly renal (about 90%) as unchanged drug and metabolites, with approximately 10% excreted in feces via biliary elimination. Chlorpheniramine is metabolized in the liver and excreted renally as metabolites (about 70-80%) and unchanged drug (about 10-20%), with minor fecal excretion.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine/Decongestant